Engineering CD4+ T Cells to Enhance Cancer Immunity. (2020)
Attributed to:
Precision targeting of mTOR in conventional and MHC class I-restricted anti-tumour CD4+ T cells
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3390/cells9071721
PubMed Identifier: 32708397
Publication URI: http://europepmc.org/abstract/MED/32708397
Type: Journal Article/Review
Volume: 9
Parent Publication: Cells
Issue: 7
ISSN: 2073-4409